Avid Bioservices (CDMO) Appoints Esther M. Alegria to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Avid Bioservices (CDMO) PT Raised to $29 at Stephens
July 1, 2021 6:26 AM EDTStephens analyst Jacob Johnson raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $26.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) PT Raised to $29 at Craig-Hallum
June 30, 2021 8:49 AM EDTCraig-Hallum analyst Matthew Hewitt raised the price target on Avid Bioservices (NASDAQ: CDMO) to $29.00 (from $21.00) while maintaining a Buy rating.
The analyst commented, "With the stock hitting 52-week highs, expectations were high going into Avids Q4 earnings report, but in our... More
Avid Bioservices (CDMO) PT Raised to $27 at RBC Capital
June 30, 2021 6:12 AM EDTRBC Capital analyst Sean Dodge raised the price target on Avid Bioservices (NASDAQ: CDMO) to $27.00 (from $21.00) while maintaining a Outperform rating.... More
Avid Bioservices (CDMO) PT Raised to $28 at KeyBanc
June 30, 2021 4:40 AM EDTKeyBanc analyst Paul Knight raised the price target on Avid Bioservices (NASDAQ: CDMO) to $28.00 (from $22.00) while maintaining a Overweight rating.... More
Avid Bioservices (CDMO) Reports Q4 Loss of $0.04/sh
June 29, 2021 4:11 PM EDTAvid Bioservices (NASDAQ: CDMO) reported Q4 EPS of ($0.04), versus ($0.11) reported last year. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $21.6 million.
GUIDANCE:
Avid Bioservices sees FY2021 revenue of $115-117 million, versus the consensus of $89.9... More
